摘要
近年来许多研究证实了非编码RNA在调整基因表达方面的重要作用。研究主要集中于短非编码基因,如miRNAs,而长非编码RNA(lncRNA)现对来说研究较少。长非编码基因能从基因间,基因内或特殊染色体区域进行转录。与miRNAs相比,lncRNAs有复杂的二级和三级结构,使得它们能连接蛋白质,RNA,DNA和执行基础功能。许多研究表明细胞外ncRNAs在正常人和病人血液中都能循环。大部分参与循环的ncRNAs都分布在使它们高度稳定的脂质或者脂蛋白囊泡中,如凋亡小体,大多孔脂质体或者外来体。癌症病人与正常人血液中参与循环的ncRNAs可能成为新的诊断标记物。HOTAIR是同源框蛋白转录反义RNA,存在于HOXC核心区,它能够抑制HOXD核心区转录后期。HOTAIR参与了许多主要肿瘤的演变,HOTAIR的表达能促进(肿瘤)入侵和转移。这篇综述描述了lncRNA HOTAIR可能成为参与循环的标记物的实验证据。
关键词: 长非编码RNA,HOTAIR,参与循环的长非编码RNA,癌症,血液
Current Drug Targets
Title:LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Volume: 18 Issue: 1
Author(s): Gerardo Botti, Laura Marra, Maria Gabriella Malzone, Annamaria Anniciello, Chiara Botti, Renato Franco, Monica Cantile
Affiliation:
关键词: 长非编码RNA,HOTAIR,参与循环的长非编码RNA,癌症,血液
摘要: In the recent years the importance of the role played by non-coding RNA on the regulation of gene expression was increased by numerous studies. The research mainly focused on small ncRNAs, such as miRNAs, while the functions of long non-coding RNA (lncRNA) have been much less studied. lncRNAs can be transcribed from intergenic, intragenic or specific chromosomal regions. Compared to miRNAs, lncRNAs have a complex secondary and tertiary structure which allows to bind proteins, RNA, DNA and to carry out their regulatory functions. Several studies showed that extracellular ncRNAs can circulate in the blood of both healthy and diseased patients. Most of the circulating ncRNAs are included in lipid or lipoprotein vesicles, such as apoptotic bodies, macrovesicles or exosomes, in which they are highly stable. The presence of circulating ncRNAs in the blood of cancer patients versus normal subjects suggested the possibility that these molecules may represent new diagnostic markers. HOTAIR is a HOX transcript antisense RNA, located in the HOXC locus, able to repress transcription in the posterior region of the HOXD locus. HOTAIR has been <involved in the evolution of several primary tumors, wherein increase of HOTAIR expression has endorsed invasion and metastasis. In this review, we describe the experimental evidences on the potential role as circulating marker of lncRNA HOTAIR.
Export Options
About this article
Cite this article as:
Gerardo Botti, Laura Marra, Maria Gabriella Malzone, Annamaria Anniciello, Chiara Botti, Renato Franco, Monica Cantile , LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases, Current Drug Targets 2017; 18 (1) . https://dx.doi.org/10.2174/1389450117666151209122950
DOI https://dx.doi.org/10.2174/1389450117666151209122950 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Thymidine Phosphorylase in Biomodulation of Fluoropyrimidines
Current Pharmaceutical Biotechnology Androgen Receptor Cofactors in Prostate Cancer: Potential Therapeutic Targets of Castration-Resistant Prostate Cancer
Current Cancer Drug Targets Strategies and Techniques for Multi-Component Drug Design from Medicinal Herbs and Traditional Chinese Medicine
Current Topics in Medicinal Chemistry Multiple Sclerosis: Current and Future Treatment Options
Endocrine, Metabolic & Immune Disorders - Drug Targets Natural Products as a Promising Therapeutic Strategy to Target Cancer Stem Cells
Current Medicinal Chemistry Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders
Current Molecular Pharmacology Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry Gender Effects on Rat Metabolism of AMG 900, an Orally Available Small Molecule Aurora Kinase Inhibitor
Drug Metabolism Letters The Rapidly Changing Composition of the Global Street Drug Supply and its Effects on High-risk Groups for COVID-19
Current Psychopharmacology Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry The Significance of COX-2 and COX-2 Inhibitors in Liver Fibrosis and Liver Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Sigma-2 Receptor Ligands: Neurobiological Effects
Current Medicinal Chemistry Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies
Current Angiogenesis (Discontinued) Organosulfur Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Current Pharmacogenomics and Personalized Medicine Current Trends and Future Directions of Fluoroquinolones
Current Medicinal Chemistry